Seeking Alpha
29 Jan 2026, 21:09 UTC · 40w ago
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
Impact · against what's priced in
The FDA's acceptance of the OLC NDA resubmission provides a concrete regulatory catalyst for Unicycive. The fact that the previous rejection was limited to manufacturing rather than clinical efficacy increases the probability of approval for a product with competitive dosing advantages.
- UTHR+0.70
No priced-in read yet
- In context
The establishment of a PDUFA date and the clarification that the prior FDA rejection was based on third-party manufacturing rather than clinical data significantly derisks the path to approval.
Read from the article alone
Search tags
